|Day Low/High||16.75 / 17.35|
|52 Wk Low/High||10.09 / 37.00|
There is no question that we are becoming extended and ripe for some profit taking.
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
Many stocks are already at support levels and are offering opportunities to start some positions.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
This market may be extended by just about any measure, but that doesn't mean you should be fighting it.
Breadth is slightly negative as markets ease into 3-day weekend.
The applications for this distributed ledger technology are endless.
The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.
Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.